AriDBaronMD

Oncology • San Francisco, CA

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology

Chief, Division of Hematology-Oncology, California Pacific Medical Center Associate Clinical Professor, Medicine, UCSF

Join to view full profile

Dr. Baron is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baron's full profile

Already have an account?

Office
2100 Webster Street Suite 225
San Francisco, CA 94115
Phone+1 415-923-3012

Education & Training

University of California (San Francisco)/FresnoFellowship, Hematology and Medical Oncology, 1994 - 1996
University of California (San Francisco)Residency, Internal Medicine, 1991 - 1993
University of California (San Francisco)Internship, Internal Medicine, 1990 - 1991
Tufts University School of MedicineClass of 1990
Wesleyan UniversityB.A., English, 1984

Certifications & Licensure

CA State Medical License 1991 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2013
Excellence in Teaching Award, Department of Medicine (Awarded to Outstanding Teacher among Clinical Fellows by Medicine House Staff) University of California, San Francisco, 1995
Julius Krevans Award for Clinical Excellence, Department of Medicine (Awarded to Outstanding Intern) University of California, San Francisco, 1991
Alpha Omega Alpha, National Medical Honors Society 1989
Grant, Based on Academic Achievement and Demonstrated Interest in the Arts and Letters Joseph Collins Foundation, 1988
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Start of enrollment: 2007 Aug 01
Terminated
Phase 2
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Completed
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
Terminated
Phase 3
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Start of enrollment: 2014 Mar 12
Active, not recruiting
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Start of enrollment: 2015 Jul 20
Completed
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Start of enrollment: 2018 Apr 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

8233 citations
BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John D. Hainsworth
The New England Journal of Medicine. 2004-06-03
18 citations
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
Jennifer L McQuade, Hans Hammers, Helena Furberg, Andreas Engert, Thierry André
JAMA Oncology. 2023-01-01
3182 citations
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang Hyub Han, Kenji Ikeda
Lancet. 2018-03-24

Journal Articles

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwa..., Cancer Chemother Pharmacol, 1/1/2014
Lenalidomide and Rituximab in Waldenstrom’s Macroglobulinemia
Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Luis Chu, Paul Musto, Ari D. Baron, Johannes..., Clinical Cancer Res, 1/1/2009
Phase II Trial of Weekly Patupilone (EPO 906) in Patients with Castration-Resistant Prostate Cancer
Hussain, DiPaola, Baron, Higano, Tchekmedyian, Miller, Rothermel, Annals of Oncology, 1/1/2009
Hepatocellular Carcinoma: Current and Evolving Therapies
Gish R. and Baron A, Idrugs, 1/1/2008
Trastuzumab and Vinorelbine or Taxane Chemotherapy for HER-2+ Metastatic Breast Cancer: The TRAVIOTA Study
Burstein H., Keshaviah A., Baron A., Hart R., Lambert-Falls R., Marcom P., Gelman R., Winer E, Cancer, 1/1/2007
A Randomized Multicenter Study to Determine the Safety and Efficacy of the Immunoconjugate SGN-15 Plus Docetaxel for the Treatment of Non-Small Cell Lung Carcinoma
Ross H., Hart L., Swanson P., Rarick M., Figlin R., Jacobs A., McCune D., Rosenberg A., Baron A., Grove L., Thorn M., Miller D., Sing, A., Drachman J., Rudin, C., Lung Cancer, 1/1/2006
Addition of Bevacizumab (rhuMab VEGF) to Bolus IFL in the First-Line Treatment of Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase III Trial
Hurwitz, Fehrenbacher, Novotny, Cartwright, Hainsworth, Heim, Berlin, Baron, Griffing, Holmgren, Ferrara, Fyfe, Rogers, Ross, Kabbinnavar, New England Journal of Medicine, 1/1/2004
Simultaneous Anti-Androgen Withdrawal and Treatment with Ketoconazole in Patients with Advanced Hormone Refractory Prostate Cancer
Small E.S., Baron A.D., Bok R, Cancer, 1/1/1997
Ketoconazole Retains Activity in Advanced Prostate Cancer Patients Who Have Progressed Despite Flutamide Withdrawal
Small E.J., Baron A.D., Flippin L, Journal of Urology, 1/1/1997
Sweet’s Syndrome During G-CSF Therapy
Parks J., Mehrotra B., Barnett B., Baron A., Venook A, Annals of Internal Medicine, 1/1/1992
Join now to see all

Abstracts/Posters

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Patients with Elevated ?-Fetoprotein from the Randomized Phase II...
Andrew X. Zhu, Baek-Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Tulio Eduardo Flesch ..., Proc ASCO/GI, 1/1/2015
The DASH Study: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocellular Carcinoma
Ghassan K Abou-Alfa, Rebecca A. Miksad, Martin E. Gutierrez, Mohamedtaki A. Tejani, Manish R. Sharma, Weijing Sun, Charles A. Henderson, Ari D. Baron, Olugbenga O. Olo..., Proc ASCO/GI, 1/1/2015
Ramucirumab(RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC); Analysis of Patient’s by Child-Pugh Score
Ian Chau, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weissinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuk..., Proc ASCO, 1/1/2015
A Randomized Open Label Multi-Institution Phase II Study of the Combination of Bevacizumab (B) and Erlotinib (E) Compared to Sorafenib (S) in the First-Line Treatment ...
Thomas, MB, Garrett-Mayer, E, Anis, M, Anderton, K, Bentz, T, Adelman, A, Brisendine, A, Duddalwar, V, Weiss, G, Siegel, AB, Bendell, J, Baron, A, El-Khoueiry, A, Proc ASCO/GI, 1/1/2015
Ramuciumab (RAM; IMC-1121B) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib: Results from the ...
A Zhu, B-Y. Ryoo, C-J. Yen, M Kudo, R. Poon, D. Pastorelli, J-F. Blanc, H. Chung, A. Baron, T. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I, Chau, S-C. C..., Proc ESMO, 1/1/2014
A Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting STEAP1, in Patients with Metastatic Castration-Resistant Prostate Cancer
Danila DC, Szmulewitz RZ, Baron A, Higano CS, Scher HI, Morris M, Gilbert H, Brunstein F, Lemahieu V, Kabbarah O, Fine BM Maslyar DJ, Vasihampayan, U, Proc ASCO, 1/1/2014
A QTc study of cabazitaxel in patients with advanced solid tumors.
J.L. Wade, Shaker Dakhil, Ari Baron, Sylvie Rottie, Fredrick Millard, Daugaard Gedske, Jean-Pascale Machiels, William Conkright, Sunile Sharma, Patricial Soetekouw, Je..., Proc ASCO/GU, 1/1/2012
Phase 1b Study of Drozitumab Combined with Cetuximab (CET) + Irinotecan (IRI) or with FOLFIRI + Bevacizumab (BV) in Previously Treated Patients (patient’s) with Metast...
Ari D Baron, Cindy L O’Bryant, Younjeong Choi, Avi Ashkenazi, Stephanie Royer-Joo, Chia C Portera, Proc ASCO, 1/1/2011
Phase II trial of gemcitabine (G), oxaliplatin (O), an erlotinib (T) for the treatment of hepatocellular carcinoma (HCC)and biliary tree cancers (BTC)
Y.Z. Patt, A.D. Baron, V. A. Parks, A. Small, M. Roach, S. Lee, F. Lee, Proc ASCO, 1/1/2010
Treatment of anal carcinoma in HIV-positive males: A single institution experience.
A. Parthasarathy, D.L. Glaubiger, K. M. Grant, A.D. Baron, Proc ASCO/GI, California Pacific Medical Center, San Francisco, CA, 1/1/2008
Trastuzumab and Vinorelbine or Taxane Chemotherapy for HER-2+ Metastatic Breast Cancer: The TRAVIOTA Study.
Burstein H., Keshaviah A., Baron A., Hart R., Lambert-Falls R., Marcom P., Gelman R., Winer E, Proc ASCO, 1/1/2006
Influence of Hepatic Dysfunction on Safety, Tolerability and Pharmacokinetics of PTK787/ZK 222584 in Patients with Unresectable Hepatocellular Carcinoma.
Koch, Baron, Roberts, Junker, Palacay-Ramona, Masson, Laurent, Kay, Wiedenmann, Cebon, Proc ASCO, 1/1/2005
Phase II Trial of Weekly Patupilone (EPO 906) in Patients with Castration-Resistant Prostate Cancer.
Hussain, DiPaola, Baron, Higano, Tchekmedyian, Miller, Rothermel, Proc ASCO, 1/1/2004
Simultaneous Anti-Androgen Withdrawal and Treatment with Ketoconazole in Patients with Advanced Hormone Refractory Prostate Cancer.
Small E.S., Baron A.D., Bok R, Proc ASCO, 1/1/1996
Pseudomonas Aeruginosa Bronchopulmonary Infection in Late HIV Disease.
Baron A., & Hollander, H, American Review of Respiratory Diseases; 8th International AIDS Conference, Amsterdam, 1/1/1993
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member